| 1 |
Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer[J]. Lancet, 2021, 398(10299): 535-554.
|
| 2 |
喻星豪，黄娜，刘罡. 肺癌的靶向与免疫联合治疗的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(2): 330-333.
|
| 3 |
Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015[J]. J Thorac Oncol, 2022, 17(3): 362-387.
|
| 4 |
Baldovini C, Rossi G, Ciarrocchi A. Approaches to tumor classification in pulmonary sarcomatoid carcinoma[J]. Lung Cancer (Auckl), 2019, 10: 131-149.
|
| 5 |
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification[J]. J Thorac Oncol, 2015, 10(9): 1243-1260.
|
| 6 |
Elshatlawy M, Sampson J, Clarke K, et al. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries[J]. Mol Oncol, 2023, 17(6): 950-963.
|
| 7 |
Chen X, Zhang Y, Lu J, et al. Pulmonary sarcomatoid carcinoma with ALK rearrangement: frequency, clinical-pathologic characteristics, and response to ALK inhibitor[J]. Transl Oncol, 2017, 10(2): 115-120.
|
| 8 |
Song X, Zhong H, Qu X, et al. Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis-targeting chimeras[J]. Med Comm (2020), 2021, 2(3): 341-350.
|
| 9 |
De Lucia A, Mazzotti L, Gaimari A, et al. Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy[J]. Front Immunol, 2025, 16: 1515748.
|
| 10 |
Wen Y, Jiang T, Wu X, et al. Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis[J]. Ther Adv Med Oncol, 2022, 14: 17588359221116607.
|
| 11 |
Wu L, Zou Z, Li Y, et al. Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs[J]. J Transl Med, 2024, 22(1): 585.
|
| 12 |
Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase Ⅲ CROWN study[J]. J Clin Oncol, 2024, 42(29): 3400-3409.
|
| 13 |
Seto T, Hayashi H, Satouchi M, et al. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study[J]. Cancer Sci, 2020, 111(10): 3726-3738.
|
| 14 |
Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer[J]. N Engl J Med, 2020, 383(21): 2018-2029.
|
| 15 |
Niu D, Zhao S, Kong S, et al. Elucidation of lorlatinib toxicity mechanisms through GC-MS-based metabolomics[J]. J Pharm Biomed Anal, 2025, 265: 117017.
|
| 16 |
Verdura S, Encinar JA, Fernández-Arroyo S, et al. Silibinin suppresses the hyperlipidemic effects of the ALK-tyrosine kinase inhibitor lorlatinib in hepatic cells[J]. Int J Mol Sci, 2022, 23(17): 9986.
|
| 17 |
IAP/APA/EPC/IPC/JPS Working Group. Electronic address: info@internationalpancreatology.org, IAP/APA/EPC/IPC/JPS Working Group. International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025: Supported and Endorsed by the American Pancreatic Association, European Pancreatic Club, Indian Pancreas Club, and Japan Pancreas Society[J]. Pancreatology, 2025, 25(6): 770-814.
|
| 18 |
McGee K, Stone NJ, Wadhwani S, et al. A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy[J]. J Oncol Pharm Pract, 2021, 27(8): 2010-2013.
|
| 19 |
Teng T, Chua B, Lim PK, et al. Occam′s razor or Hickam′s dictum-COVID-19 is not a textbook aetiology of acute pancreatitis: A modified Naranjo Score appraisal[J]. World J Gastroenterol, 2023, 29(13): 2050-2063.
|
| 20 |
Tenner S, Vege SS, Sheth SG, et al. American college of gastroenterology guidelines: management of acute pancreatitis[J]. Am J Gastroenterol, 2024, 119(3): 419-437.
|
| 21 |
《高甘油三酯血症性急性胰腺炎诊治急诊专家共识》专家组. 高甘油三酯血症性急性胰腺炎诊治急诊专家共识[J]. 中国全科医学，2021, 24(30): 3781-3793.
|
| 22 |
Liu G, Mazieres J, Stratmann J, et al. A pragmatic guide for management of adverse events associated with lorlatinib[J]. Lung Cancer, 2024, 191: 107535.
|
| 23 |
Reed M, Rosales AS, Chioda MD, et al. Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners[J]. Adv Ther, 2020, 37(6): 3019-3030.
|
| 24 |
Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib[J]. Oncologist, 2019, 24(8): 1103-1110.
|
| 25 |
Blais N, Adam JP, Nguyen J, et al. Evaluation and management of dyslipidemia in patients treated with lorlatinib[J]. Curr Oncol, 2021, 28(1): 265-272.
|
| 26 |
Alonso R, Cuevas A, Cafferata A. Diagnosis and management of statin intolerance[J]. J Atheroscler Thromb, 2019, 26(3): 207-215.
|
| 27 |
de Pretis N, Amodio A, Frulloni L. Hypertriglyceridemic pancreatitis：Epidemiology, pathophysiology and clinical management[J]. United European Gastroenterol J, 2018, 6(5): 649-655.
|
| 28 |
中国医疗保健国际交流促进会肿瘤内科学分会，中国医师协会肿瘤医师分会. 伊鲁阿克治疗间变性淋巴瘤激酶融合基因阳性局部晚期或转移性非小细胞肺癌中国专家共识(2024版)[J]. 中华肿瘤杂志，2024, 46(3): 189-205.
|